Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease

• Status: Completed
• Trial end date: 2019-02-06
• Target enrollment: 0
• Participant gender: All

Summary

36 patients with interstitial lung disease will be randomized to 1 weeks treatment with morphine hydrochloride as oral linctus 5 mg, four times a day, and 5 mg as needed up to 4 times a day, or corresponding doses of placebo.

VAS score for dyspnea will be evaluated after 1 hour and 1 week at follow up. Other questionnaires will also be evaluated (GAD-7, K-BUILD, Leicester score)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborator: Skanderbog Apotek
• Treatments: Morphine

Criteria

Inclusion Criteria:

• A diagnosis of interstitial lung disease (IPF, NSIP, RA-ILS, Scl-ILS, MCTD-ILS, asbestous, drug induced ILD, unclassified ILD)

• Dyspnea corresponding to Medial Research Councils (MRC) dyspnea score ≥ 3

• Written consent

• Age ≥ 18 years

• Competent

• For fertile women: Negative pregnancy test

• For fertile and sexually active participants: Use of safe anti-conceptionals

Exclusion Criteria:

• Ongoing infection

• Decreased lung function to a degree which makes any form of respiratory depression life threatening

• Treatment with morphine or morphine analogues

• Allergy towards morphine hydrochloride